English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 1 August 2018, 18:35 HKT/SGT
Share:
Ascletis' NDA for Its All-oral HCV Treatment Accepted by CFDA

Hangzhou and Shaoxing, China , Aug 1, 2018 - (ACN Newswire) - Ascletis announced today it has received the acceptance letter from the China Food and Drug Administration (CFDA) for Ravidasvir (RDV) new drug application (NDA). Ravidasvir in combination with Ganovo (RDV/DNV Regimen) is the first all-oral interferon-free HCV regimen developed by a domestic company in China. Phase II/III clinical trial has shown that RDV/DNV Regimen demonstrated a cure rate of 99 % ( SVR12) with a short treatment duration of 12 weeks in genotype 1 patients. In patients with baseline NS5A resistance mutations, RDV/DNV Regimen demonstrated a cure rate of 100% (SVR12).

"Ascletis was successfully listed this morning on Hong Kong Exchange as the first ever pre-revenue biotech. The NDA for our all-oral HCV regimen was accepted by CFDA in the afternoon." Jinzi J. Wu, Ph.D., Ascletis' founder, President and CEO, commented, "Two significant accomplishments on the same day reflect our unremitting effort to provide affordable and effective HCV cures to the patients and to fulfill our commitment to the investors."

Ganovo Regimen, Ascletis' first breakthrough HCV regimen, was approved on June 8 and launched on June 27, 19 days after the approval. The acceptance of the NDA for its all-oral HCV regimen enables Ascletis soon to provide two HCV treatment options for Chinese patients, strengthening its leading position in China's HCV field.


Topic: Press release summary
Sectors: Daily Finance, Daily News, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
NEC Provides Facial Recognition System for Admission Control at EU Summit  
July 17, 2019 09:03 HKT/SGT
China Animation (1566.HK) Announces Annual Results; Profit Surges by 180.8%  
July 17, 2019 08:40 HKT/SGT
Eisai's Anticancer Agent Halaven Approved for Treatment of Locally Advanced or Metastatic Breast Cancer in China  
July 17, 2019 08:20 HKT/SGT
China Medical System Holdings Ltd. (0867. HK) Strategically Introduces Overseas Launched Blockbuster Innovative Products  
July 16, 2019 18:46 HKT/SGT
WiMi Hologram (WIMI) files for listing on Nasdaq Global Market  
July 16, 2019 18:00 HKT/SGT
Qatar Financial Centre Strengthens Ties With Hong Kong  
July 16, 2019 15:45 HKT/SGT
CropLife Asia Calls on Region's Stakeholders to Work Together to Address "Unacceptable" Food Crisis  
July 16, 2019 15:00 HKT/SGT
JAXA and Toyota Commence Joint Research into Manned Pressurized Rover  
July 16, 2019 13:19 HKT/SGT
NEC Successfully Transmits Live 8K Video Using 5G with the Largest Television Station in France  
July 16, 2019 09:14 HKT/SGT
TNG FinTech Group to Develop HK's FinTech Community into a Regional Financial Powerhouse  
July 15, 2019 20:50 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575